- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Patent holdings for IPC class A61P 33/02
Total number of patents in this class: 920
10-year publication summary
30
|
35
|
45
|
51
|
62
|
68
|
68
|
81
|
65
|
16
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Novartis AG | 11238 |
22 |
CEVA Sante Animale | 683 |
16 |
Anacor Pharmaceuticals, Inc. | 84 |
12 |
Bayer Animal Health GmbH | 300 |
10 |
Universidade Federal de Minas Gerais - Ufmg | 193 |
10 |
Universidad de Granada | 285 |
9 |
Fundacao Oswaldo Cruz | 99 |
8 |
Institut de Recherche pour le Developpement (ird) | 155 |
8 |
Nihon Nohyaku Co., Ltd. | 313 |
8 |
Vyera Pharmaceuticals, LLC | 10 |
8 |
Kimberly-clark Worldwide, Inc. | 5854 |
7 |
Centre National de La Recherche Scientifique | 9632 |
7 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
7 |
President and Fellows of Harvard College | 5792 |
7 |
Consejo Superior de Investigaciones Cientificas (csic) | 1254 |
7 |
University of Dundee | 194 |
7 |
Kao Corporation | 4843 |
6 |
The United States of America, as represented by the Secretary of Agriculture | 1033 |
6 |
Washington University | 1473 |
6 |
Glaxosmithkline Intellectual Property Development Limited | 723 |
5 |
Other owners | 744 |